Discovery of a Selective S1P(1) Receptor Agonist Efficacious at Low Oral Dose and Devoid of Effects on Heart Rate

[Image: see text] Gilenya (fingolimod, FTY720) was recently approved by the U.S. FDA for the treatment of patients with remitting relapsing multiple sclerosis (RRMS). It is a potent agonist of four of the five sphingosine 1-phosphate (S1P) G-protein-coupled receptors (S1P(1) and S1P(3−5)). It has be...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Demont, Emmanuel H., Andrews, Benjamin I., Bit, Rino A., Campbell, Colin A., Cooke, Jason W. B., Deeks, Nigel, Desai, Sapna, Dowell, Simon J., Gaskin, Pam, Gray, James R. J., Haynes, Andrea, Holmes, Duncan S., Kumar, Umesh, Morse, Mary A., Osborne, Greg J., Panchal, Terry, Patel, Bela, Perboni, Alcide, Taylor, Simon, Watson, Robert, Witherington, Jason, Willis, Robert
Formato: Artigo
Idioma:Inglês
Publicado em: American Chemical Society 2011
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4018134/
https://ncbi.nlm.nih.gov/pubmed/24900328
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/ml2000214
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados